Medtronic admits its results will be below expectations in face of fierce competition in ICD (implantable cardioverter defibrillator) market
This article was originally published in Clinica
Medtronic has conceded that its first-quarter results and earnings per share for 1998 will be below its own expectations and will not meet analysts' published estimates. The company's share price fell almost 10% to $52.50 on the news before recovering to around $56 a share.
You may also be interested in...
Indian drug makers appear confident of meeting both domestic and global requirements for hydroxychloroquine sulphate after India relaxed export curbs on the product, subject to strict monitoring, against the backdrop of requests from global heads of government for supplies of the potential treatment for COVID-19.
CEO breaks down to Scrip how the Hong Kong-based company managed its way through the coronavirus outbreak in China, saying improvisation was critical.
GNC announces "significant" store and management staff furloughs and other cost-cutting moves "to protect the long-term prospects for the business." Vitamin Shoppe told customers that its stores remain open though it reduced business hours.